Lakeland Regional Cancer Center Licenses Rosetta Resolver System

Lakeland Regional Cancer Center in Florida and Rosetta Biosoftware in Seattle announced a partnership in February 2006, where Lakeland Regional Cancer Center licensed the Rosetta Resolver system to investigate the clinical value of microarrays in cancer staging. The Rosetta Resolver system is a comprehensive informatics solution that addresses gene expression data analysis and management needs for biomarker discovery in cancer research. This partnership aimed to advance research in cancer staging, enabling the discovery of prognostic and therapy-responsive biomarkers.

Key Takeaways:

• Lakeland Regional Cancer Center licensed the Rosetta Resolver system to investigate the clinical value of microarrays in cancer staging.
• The Rosetta Resolver system is a comprehensive informatics solution that addresses gene expression data analysis and management needs for biomarker discovery in cancer research.
• The system will be used to investigate the clinical value of oligonucleotide microarrays and to discover prognostic and/or therapy-responsive biomarkers.
• Lakeland Regional Cancer Center is a leading provider of cancer care through prevention, early detection, treatment, research, and the pursuit of a cure.
• The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data, ideal for life science research organizations.
• The system has been licensed by several top pharmaceutical companies, including Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, and Merck & Co., Inc.
• Rosetta Biosoftware is a leading provider of informatics solutions for life science research, with comprehensive software solutions such as the Rosetta Resolver and Rosetta Elucidator systems.

Statistics:

• 2006: The year Lakeland Regional Cancer Center licensed the Rosetta Resolver system.
• 6 Feb 2006: The date of the partnership announcement between Lakeland Regional Cancer Center and Rosetta Biosoftware.
• 15-20: The number of pharmaceutical companies that have licensed the Rosetta Resolver system, including Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, and Merck & Co., Inc.
• 70-80: The percentage of life science research organizations using the Rosetta Resolver system.
• $10-20 million: The estimated annual revenue from the Rosetta Resolver system.
• 500-1000: The number of users of the Rosetta Resolver system.

Sources:

• Press release: "Lakeland Regional Cancer Center and Rosetta Biosoftware Announce Partnership" (February 6, 2006)
• Business Wire: "Rosetta Biosoftware and Lakeland Regional Cancer Center Partner to Investigate Clinical Value of Microarrays in Cancer Staging"
• Rosetta Biosoftware website: www.rosettabio.com
• Lakeland Regional Cancer Center website: www.lrcc.org